Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial - PubMed (original) (raw)

Randomized Controlled Trial

doi: 10.1093/eurjhf/hfr020. Epub 2011 Mar 23.

Svetlana Apostolovic, Simone Inkrot, Elvis Tahirovic, Agnieszka Töpper, Felix Mehrhof, Christiane Prettin, Biljana Putnikovic, Aleksandar N Neskovic, Mirjana Krotin, Dejan Sakac, Mitja Lainscak, Frank Edelmann, Rolf Wachter, Thomas Rau, Thomas Eschenhagen, Wolfram Doehner, Stefan D Anker, Finn Waagstein, Christoph Herrmann-Lingen, Goetz Gelbrich, Rainer Dietz; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure

Collaborators, Affiliations

Randomized Controlled Trial

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial

Hans-Dirk Düngen et al. Eur J Heart Fail. 2011 Jun.

Abstract

Aims: Various beta-blockers with distinct pharmacological profiles are approved in heart failure, yet they remain underused and underdosed. Although potentially of major public health importance, whether one agent is superior in terms of tolerability and optimal dosing has not been investigated. The aim of this study was therefore to compare the tolerability and clinical effects of two proven beta-blockers in elderly patients with heart failure.

Methods and results: We performed a double-blind superiority trial of bisoprolol vs. carvedilol in 883 elderly heart failure patients with reduced or preserved left ventricular ejection fraction in 41 European centres. The primary endpoint was tolerability, defined as reaching and maintaining guideline-recommended target doses after 12 weeks treatment. Adverse events and clinical parameters of patient status were secondary endpoints. None of the beta-blockers was superior with regards to tolerability: 24% [95% confidence interval (CI) 20-28] of patients in the bisoprolol arm and 25% (95% CI 21-29) of patients in the carvedilol arm achieved the primary endpoint (P= 0.64). The use of bisoprolol resulted in greater reduction of heart rate (adjusted mean difference 2.1 b.p.m., 95% CI 0.5-3.6, P= 0.008) and more, dose-limiting, bradycardic adverse events (16 vs. 11%; P= 0.02). The use of carvedilol led to a reduction of forced expiratory volume (adjusted mean difference 50 mL, 95% CI 4-95, P= 0.03) and more, non-dose-limiting, pulmonary adverse events (10 vs. 4%; P < 0.001).

Conclusion: Overall tolerability to target doses was comparable. The pattern of intolerance, however, was different: bradycardia occurred more often in the bisoprolol group, whereas pulmonary adverse events occurred more often in the carvedilol group. This study is registered with controlled-trials.com, number ISRCTN34827306.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Participant flow through the study. Target dose based on the 2005 European Society of Cardiology guidelines.

Figure 2

Figure 2

Predictors of tolerability. Filled diamonds indicate factors significantly related to outcome.

Figure 3

Figure 3

Kaplan–Meier estimate showing that the percentage of patients reaching the ascending dose levels in line with the titration scheme did not differ between groups. White circles indicate bisoprolol and black circles indicate carvedilol.

Similar articles

Cited by

References

    1. McMurray JJ, Stewart S. Heart failure: epidemiology, aetiology, and prognosis of heart failure. Heart. 2000;83:596–602. - PMC - PubMed
    1. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13. - PubMed
    1. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF) Lancet. 1999;353:2001–2007. - PubMed
    1. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of Carvedilol on the Morbidity of Patients with Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation. 2002;106:2194–2199. - PubMed
    1. Calvert MJ, Shankar A, McManus RJ, Ryan R, Freemantle N. Evaluation of the management of heart failure in primary care. Fam Pract. 2009;26:145–153. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources